Pharmaceuticals

Brain Tumor Drugs Market Outlook 2026–2030 Exploring Opportunities

March 18, 2026March 18, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Brain Tumor Drugs Market During The Forecast Period 2026–2030?

The brain tumor drugs market size has shown strong growth over recent years. It is projected to increase from $4.03 billion in 2025 to $4.26 billion in 2026, at a compound annual growth rate (CAGR) of 5.7%. This historical growth can be attributed to the rising prevalence of brain tumors, significant advancements in chemotherapy drugs, increased awareness regarding symptom management, the development of hormone therapies, and the introduction of novel anticonvulsants.

The brain tumor drugs market size is projected to undergo substantial expansion in the coming years. By 2030, it is forecast to attain $5.5 billion, growing at a compound annual growth rate (CAGR) of 6.6%. The anticipated growth within the forecast period is driven by the advancement of precision medicine, the incorporation of ai in drug discovery, increased r&d in oncology, greater healthcare expenditure, and the escalating adoption of targeted therapies. Key trends during this period feature personalized chemotherapy treatments, a rise in hormone therapy applications, sophisticated pain management drugs, the increasing utilization of anticonvulsants in symptom control, and the broadening of brain tumor drug pipelines.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2588&type=smp

Which Major Factors Are Driving The Expansion Of The Brain Tumor Drugs Market?

The increasing number of patients undergoing chemotherapy is projected to stimulate the growth of drugs for brain tumors. This medical approach utilizes powerful medications designed to target and eliminate rapidly proliferating cells, such as those found in cancer. Serving as a primary treatment modality for brain tumors, the advent and accessibility of potent chemotherapy drugs have profoundly influenced the overall effectiveness of therapies. The success of chemotherapy is pivotal in enhancing patient survival and elevating their quality of life, thereby molding the market’s trajectory. For instance, in July 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, in the United States, more than 1 million cancer patients receive chemotherapy or radiation each year. Consequently, the increasing population of patients undergoing chemotherapy is propelling the expansion of the brain tumor drug market.

What Market Segments Are Evaluated Within The Brain Tumor Drugs Market?

The brain tumor drugs market covered in this report is segmented –

1) By Drugs: Temozolomide, Bevacizumab, Other Drugs

2) By End User: Hospital Pharmacies, Retail Pharmacies Or Drug Stores, Other End-Users

3) By Mechanism of Action: Chemotherapy Agents, Targeted Therapy, Hormone Therapy

Subsegments:

1) By Temozolomide: Oral Formulation, Injectable Formulation

2) By Bevacizumab: Monoclonal Antibody Therapy, Combination Therapy With Chemotherapy

3) By Other Drugs: Carmustine, Lomustine, Etoposide, Irinotecan, Novantrone (Mitoxantrone)

What Industry Trends Are Redefining The Brain Tumor Drugs Market?

Leading companies within the brain tumor drugs market are prioritizing technological innovations, such as targeted RAF kinase inhibitors, to fulfill the increasing demand for precision oncology treatments. These treatments aim to target specific genetic mutations found in brain tumors, thereby reducing systemic toxicity and enhancing patient outcomes. A RAF kinase inhibitor functions as a medication specifically designed to obstruct the activity of RAF proteins, which are components of the MAPK signaling pathway, consequently hindering tumor cell proliferation. This strategy stands in contrast to conventional chemotherapies, which indiscriminately destroy rapidly dividing cells and frequently lead to broader systemic adverse effects. For example, in November 2025, Day One Biopharmaceuticals, a US-based biotechnology company, launched OJEMDA (tovorafenib), an innovative therapy for pediatric patients with relapsed or refractory low-grade gliomas exhibiting BRAF fusions or V600 mutations. Tovorafenib is an orally administered, once-weekly, brain-penetrant inhibitor that precisely targets mutant RAF proteins, ensuring robust central nervous system exposure and a mechanism specifically tailored to the tumor’s molecular driver. Its notable attributes include strong selectivity, reduced systemic toxicity when compared to traditional chemotherapy, and its suitability for pediatric patients. This product signifies a substantial stride in genetically guided therapeutic interventions for childhood brain tumors.

Who Are The Top Market Participants Influencing The Brain Tumor Drugs Market?

Major companies operating in the brain tumor drugs market are F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Pfizer Inc., Merck & Co. Inc., CordenPharma, Eisai Co. Ltd., Emcure Pharmaceuticals Limited, Y-mAbs Therapeutics, Roche India, Novartis Oncology, Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz Biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Astellas Pharma Inc, Otsuka Pharmaceutical Co. Ltd, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc. (UK), AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celgene Corporation, Johnson & Johnson, Eli Lilly and Company, Sandoz AG, Eurofarma Laboratórios S.A., TUTEUR Argentina, The Takeda Pharmaceutical Company Limited, Pierre Fabre Group, Celnova Pharma, Pfizer S.R.L., Teva Pharmaceutical Industries Ltd., BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Eurolab, Aspen, Adcock Ingram.

Read the full brain tumor drugs market report here:

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Which Region Currently Holds The Largest Share Of The Brain Tumor Drugs Market?

North America was the largest region in the brain tumor drugs market in 2025. Middle East is expected to be the fastest-growing region in the global brain tumor drugs market share during the forecast period. The regions covered in the brain tumor drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Brain Tumor Drugs Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2588&type=smp

Browse Through More Reports Similar to the Global Brain Tumor Drugs Market 2026, By The Business Research Company

Brain Tumor Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Pontine Glioma Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/pontine-glioma-drugs-global-market-report

Adult Malignant Glioma Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795